Doliprane, considered a basic medicine and preferred by the French, is approaching the United States. Sanofi confirmed, Monday October 21, that it was joining forces with the American investment fund CD&R to potentially cede control of its subsidiary which markets the drug. The project of this sale arouses great emotion in France. After exclusive negotiations, the government says it has obtained sufficient guarantees for the maintenance of the subsidiary in France. The decryption by Marc Ivaldi, professor at the Toulouse School of Economics, specialist in industrial economics.
